Introduction {#Sec1}
============

Sepsis is a potentially life-threatening systemic inflammatory response to infection which can result in multisystem organ dysfunction (severe sepsis) and refractory hypotension (septic shock) \[[@CR1]\]. Sepsis is a complex, heterogeneous condition that can be caused by any infectious organism, with Gram-positive infections often predominating \[[@CR2]\]. A majority of septic patients have a pulmonary source of infection, such as pneumonia, which results in acute respiratory distress syndrome \[[@CR1]\]. Dysfunction of cardiovascular, hepatic, renal and central nervous systems can also occur in severe sepsis \[[@CR3]\]. The incidence of severe sepsis is increasing, due to an increasingly aging population \[[@CR4]\], and is currently the leading cause of death in critically ill patients, with mortality rates of 30--50 % \[[@CR5]\]. The Surviving Sepsis Campaign has recommended a number of strategies for the management of severe sepsis and septic shock, including fluid resuscitation, infection control, and respiratory and central nervous system support \[[@CR6]\] and, despite an increase in incidence, mortality rates appear to be declining \[[@CR7]\].

Septic shock is characterised by severe alterations in the cardiovascular system, including ineffective tissue oxygenation, inappropriate peripheral vasodilation, myocardial dysfunction and altered blood flow distribution, resulting in hypotension refractory to intravenous fluid administration \[[@CR1], [@CR8]\]. Septic shock is typically managed through the administration of catecholamine vasopressors (dopamine, norepinephrine or epinephrine), with norepinephrine being the preferred vasoconstrictor \[[@CR9]\]. Vasopressin is also recommended in the Surviving Sepsis Campaign guidelines to raise mean arterial pressure to target or to decrease the norepinephrine dose \[[@CR6]\]. The Vasopressin and Septic Shock Trial (VASST) indicated that vasopressin provided equivalent mortality rates to norepinephrine in patients already receiving vasopressors \[[@CR10]\]. Exogenous vasopressor administration to patients with severe sepsis and septic shock, however, can result in adverse side effects such as decreased cardiac output and cardiac arrest, mesenteric ischaemia, skin necrosis, digital ischaemia and hyponatraemia \[[@CR11]\].

Recent pre-clinical and clinical studies have indicated a potential role for ascorbate in ameliorating the pathophysiology of sepsis \[[@CR12]--[@CR14]\]. Numerous studies of septic animals administered high-dose ascorbate have shown improved microvascular changes and survival (reviewed in \[[@CR14]\]). A number of mechanisms have been proposed for ascorbate's observed activities in sepsis, but these have primarily focused on its antioxidant and anti-inflammatory functions, including its effects on signal transduction pathways in vascular cells (reviewed in \[[@CR13]\]). In contrast, very little attention has been paid to ascorbate's enzyme cofactor activities, particularly its role in the synthesis of vasopressors \[[@CR15]\]. In this review we present the hypothesis that adjuvant ascorbate could support endogenous vasopressor synthesis in severe sepsis and septic shock through acting as an essential cofactor for the metallo-enzymes involved in the biosynthesis of vasoactive catecholamines and vasopressin.

Ascorbate requirements in sepsis {#Sec2}
================================

Ascorbate is an essential micronutrient with numerous important enzyme cofactor functions in the body \[[@CR15], [@CR16]\], as well as potent antioxidant properties \[[@CR17], [@CR18]\]. Humans have lost the ability to synthesise ascorbate due to mutations in the gene encoding the terminal biosynthetic enzyme, and ascorbate must therefore be obtained regularly through the diet to prevent hypovitaminosis C and the potentially fatal deficiency disease scurvy. Recommended dietary intakes for ascorbate are typically in the range of 75--110 mg/day \[[@CR19], [@CR20]\]. Enteral or parenteral nutrition administered to critically ill patients provides \~100 mg/day ascorbate. However, critically ill patients probably require significantly higher intakes of ascorbate \[[@CR21]\] due to enhanced metabolic turnover of vitamin C during the severe inflammatory response. It should also be noted that parenteral rather than enteral nutrition may be required for optimal ascorbate status in critically ill patients because intravenously administered ascorbate bypasses the rate-limiting intestinal uptake of orally administered ascorbate \[[@CR22]\].

In healthy fasting humans, circulating levels of ascorbate are typically in the range of 50--70 μmol/l, whereas levels \<23 μmol/l are considered marginally deficient (or hypovitaminosis C) and levels \<11 μmol/l are considered severely deficient and potentially scorbutic \[[@CR23]\]. Several studies have shown that ascorbate levels are low in critically ill patients (i.e. \<23 μmol/l), including those with acute respiratory infections \[[@CR24]\] and sepsis \[[@CR12], [@CR25]\], and are particularly low (i.e. \<11 μmol/l) in patients who progress to multiple organ failure \[[@CR26]\]. In some studies, ascorbate levels remained lower than those in controls, despite the patients receiving 100--500 mg/day ascorbate either enterally or parenterally \[[@CR27], [@CR28]\]. Long et al. \[[@CR27]\] demonstrated that up to 3000 mg/day ascorbate was required to return plasma levels of critically ill patients to normal (i.e. 68 μmol/l).

Interestingly, in animals that are able to synthesise ascorbate in their livers, studies have shown increased endogenous synthesis of ascorbate when the animals are exposed to stress \[[@CR29], [@CR30]\]. We have also observed enhanced mRNA expression of the ascorbate synthesising enzyme gulonolactone oxidase in lipopolysaccharide-treated mice (R. Natarajan, unpublished observations). Enhanced ascorbate synthesis has also recently been shown in mice exposed to tumour burden \[[@CR31]\]. These studies suggest an important physiological requirement for ascorbate in conditions of stress and disease burden. Other studies have shown up to an eight-fold enhancement in the synthesis of ascorbate in animals exposed to drugs, including hypnotics (sedatives), analgesics and muscle relaxants \[[@CR32], [@CR33]\], probably as a compensatory mechanism for enhanced metabolism of ascorbate following drug administration \[[@CR33]\]. Therefore, it is conceivable that patients with severe infection in intensive care may have enhanced ascorbate requirements not only due to the infectious disease process, but also because of the administration of sedatives and other drugs.

Ascorbate's role in vasopressor synthesis {#Sec3}
=========================================

Cases of scurvy, the clinical presentation of severe ascorbate deficiency, have been reported in critically ill patients in intensive care (Table [1](#Tab1){ref-type="table"}) \[[@CR34]--[@CR36]\]. One case presented with multiple organ dysfunction and the intravenous administration of ascorbate resulted in improved cardiovascular functioning within 24 h, particularly increased arterial pressure, decreased heart rate, normalised central venous pressure and a decreased need for catecholamines \[[@CR35]\]. Another case exhibited typical symptoms of scurvy as well as severe orthostatic hypotension that failed to respond to fluids \[[@CR36]\]. The patient's ascorbate levels were undetectable and the orthostatic hypotension resolved within 24 h of ascorbate replacement. The authors suggested that the pathogenesis of orthostatic hypotension in the setting of scurvy could result from impaired catecholamine synthesis. Vasopressin may also play a role in preventing or minimising orthostatic hypotension \[[@CR37]\], indicating a possible link between ascorbate deficiency and vasopressin insufficiency in this case \[[@CR36]\]. High-dose intravenous ascorbate administration to severely burned patients has been shown to decrease the resuscitation volume required \[[@CR38]\] and also to decrease the need for vasopressors in some patients (Table [1](#Tab1){ref-type="table"}) \[[@CR39]\].Table 1Summary of studies of ascorbate administration with vasopressor-related endpointsStudy typeStudy groupInterventionFindingsReferencePre-clinical24 rats (8/group)Centrally administered ascorbate (0, 200, 600 nmol)↑ vasopressin release\[[@CR62]\]↑ antidiuresis↑ natriuresisCase reportHospital patientIntravenous ascorbate (1,500 mg/day)↑ arterial pressure\[[@CR35]\]↓ heart rateNormalised central venous pressure↓ need for catecholaminesImproved multiple organ dysfunctionCase reportHospital patientOral ascorbate (500 mg/day)Resolution of orthostatic hypotension\[[@CR36]\]Clinical (retrospective)33 severely burned patients (16--17/group)Intravenous ascorbate (0, 66 mg/kg/h)↓ fluid requirement\[[@CR39]\]↓ number of patients requiring vasopressorsClinical (randomised, prospective)37 severely burned patients (17--18/group)Intravenous ascorbate (0, 66 mg/kg/h)↓ resuscitation fluid volume\[[@CR38]\]↑ diuresis↓ length of mechanical ventilationClinical (phase I randomised controlled trial)24 severe sepsis patients (8/group)Intravenous ascorbate (0, 50, 200 mg/kg/24 h)↓ systemic organ failure\[[@CR12]\]↑ systolic blood pressure^a^↑ mean arterial pressure^aa^Previously unpublished data (R. Natarajan and A. Fowler)*↑* increase, *↓* decrease

The recent phase I randomised controlled trial in 24 patients with severe sepsis who were administered intravenous infusions of ascorbate (0, 50 or 200 mg/kg/24 h) showed prompt reductions in Sequential Organ Failure Assessment scores in those receiving ascorbate \[[@CR12]\]. A significant reduction in the pro-inflammatory biomarkers C-reactive protein and procalcitonin was also observed, as well as attenuation of thrombomodulin levels, suggesting amelioration of vascular endothelial injury. No adverse safety events were observed in this study. Previously unpublished data from this trial indicated an increase in systolic blood pressure and mean arterial pressure in the group that received 200 mg/kg/24 h ascorbate (Fig. [1a](#Fig1){ref-type="fig"}, [b](#Fig1){ref-type="fig"}). Although these values did not reach statistical significance, probably due to low patient numbers, this finding lends support to our hypothesis that administration of ascorbate could aid in endogenous vasopressor synthesis.Fig. 1Effect of ascorbate administration on (**a**) systolic blood pressure and (**b**) mean arterial pressure in patients with severe sepsis. Patients were administered placebo (*circle*, 5 % dextrose and water, *n* = 6) or ascorbate (*inverted triangle*, 200 mg/kg/24 h, *n* = 7). The ascorbate dosage was divided into four equal doses and administered over 30 min every 6 h for 96 h in 50 ml of 5 % dextrose and water \[[@CR12]\]. Systolic blood pressure and mean arterial pressure were measured at the bedside using an arterial line (radial artery)

Ascorbate and catecholamine synthesis {#Sec4}
-------------------------------------

Catecholamine neurotransmitters and hormones (dopamine, norepinephrine and epinephrine) are synthesised within the sympathetic nervous system and the adrenal medulla (an organ with a very high ability to store vitamin C). Catecholamines increase arterial pressure through binding to and activating α-adrenergic receptors on the smooth muscle cells of the vasculature and can promote increased cardiac contractility and heart rate through binding to β-adrenergic receptors of the cardiac muscle \[[@CR40]\]. During sepsis, myocardial depression commonly occurs due to downregulation of β-adrenergic receptors and related cell signalling pathways \[[@CR41]\]. Impaired adrenal hormone synthesis has also been observed in critically ill patients and is probably a common complication in severe sepsis \[[@CR42], [@CR43]\]. Interestingly, norepinephrine levels are decreased in ascorbate-deficient animal models, particularly in the adrenal glands \[[@CR44]--[@CR46]\]. Ascorbate is also secreted from the adrenal glands as part of the stress response \[[@CR47]\], which could conceivably result in adrenal ascorbate depletion under conditions of sustained stress.

Ascorbate is required for two enzymatic steps along the catecholamine biosynthetic pathway (Fig. [2](#Fig2){ref-type="fig"}). Specifically, ascorbate is a cofactor for the copper-containing enzyme dopamine β-hydroxylase \[[@CR48], [@CR49]\]. This enzyme utilises oxygen to introduce a hydroxyl group to dopamine to form norepinephrine (Fig. [2](#Fig2){ref-type="fig"}). Epinephrine can then be formed via methyltransferase-catalysed methylation of the amine group of norepinephrine. Recent research indicates that ascorbate may also facilitate the rate-limiting step in the synthesis of dopamine via recycling the enzyme cofactor tetrahydrobiopterin (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR50]\]. This cofactor is required by the iron-containing enzyme tyrosine hydroxylase which hydroxylates the amino acid [l]{.smallcaps}-tyrosine to form the dopamine precursor [l]{.smallcaps}-DOPA. Some evidence also suggests that ascorbate enhances the synthesis of tyrosine hydroxylase itself \[[@CR50]\]. Ascorbate has also been shown to enhance both α-adrenergic and β-adrenergic receptor activity through binding to the receptor, thereby enhancing its activation by epinephrine \[[@CR51], [@CR52]\].Fig. 2Ascorbate-dependent synthesis of the catecholamine vasopressors dopamine, norepinephrine and epinephrine. Ascorbate acts as a cofactor for the metallo-enzyme dopamine hydroxylase, and also recycles the enzyme cofactor tetrahydrobiopterin. *AA* ascorbic acid, *DHA* dehydroascorbic acid, *BH* ~*4*~ tetrahydrobiopterin, *BH* ~*2*~ dihydrobiopterin

It is noteworthy that tissues where catecholamines are synthesised contain the highest levels of ascorbate in the body (i.e. the brain and adrenal glands) \[[@CR53]\], indicating that vitamin C plays a vital role in these organs. Furthermore, animal models of ascorbate deficiency have shown significant retention of the vitamin in the brain during dietary depletion \[[@CR54]--[@CR56]\], supporting the importance of ascorbate in the central nervous system. Thus, appropriate supplementation of ascorbate in sepsis may support endogenous synthesis of vasoactive catecholamines, and possibly also facilitate adrenergic receptor binding.

Ascorbate and vasopressin synthesis {#Sec5}
-----------------------------------

Vasopressin, also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH), is a peptide hormone which is synthesised in the hypothalamus as a pre-pro-hormone and subsequently stored in the posterior pituitary as the mature hormone \[[@CR57]\]. It is secreted in response to decreased blood volume, decreased arterial pressure or increased plasma osmolality, and interacts with specific receptors expressed by vascular smooth muscle cells (AVPR1a) and kidney collecting ducts (AVPR2) to cause vasoconstriction and water retention \[[@CR11]\]. The receptor AVPR1b (or AVPR3) is expressed in the anterior pituitary, and stimulation of this receptor by vasopressin enhances release of adrenocorticotrophic hormone (ACTH), thereby acting synergistically with corticotrophin-releasing hormone (CRH), and resulting in stimulation of corticosteroid synthesis in the adrenal cortex in response to stress \[[@CR11]\]. Circulating vasopressin levels increase dramatically during the initial phase of septic shock, but this is followed by a significant decline in the latter phase \[[@CR58], [@CR59]\]. Patients in late-phase septic shock have significantly lower levels of circulating vasopressin compared with patients in cardiogenic shock, despite similar hypotension \[[@CR59]\]. The decline in circulating vasopressin levels after the onset of septic shock is due to depletion of pituitary stores and possibly also impaired vasopressin synthesis \[[@CR60]\].

Ascorbate is a cofactor for the copper-containing enzyme peptidylglycine α-amidating monooxygenase (PAM) that is required for the endogenous synthesis of vasopressin \[[@CR61]\]. It is of interest to note that the pituitary gland, where the enzyme PAM is abundantly expressed, has the highest levels of ascorbate in the body \[[@CR53]\]. Thus, it is conceivable that depletion of the PAM cofactor ascorbate during sepsis may contribute to the observed decrease in vasopressin biosynthesis \[[@CR58]--[@CR60]\]. Support for a connection between ascorbate and vasopressin biosynthesis comes from an animal study whereby centrally administered ascorbate enhanced circulating levels of vasopressin and induced antidiuresis (Table [1](#Tab1){ref-type="table"}) \[[@CR62]\].

Vasopressin is synthesised as a pre-pro-hormone which undergoes sequential cleavage steps to produce pro-vasopressin and finally a glycine-extended vasopressin precursor. The carboxy-terminal glycine residue of the vasopressin precursor subsequently undergoes post-translational modification by the ascorbate-dependent enzyme PAM to generate the active carboxy-amidated hormone (Fig. [3](#Fig3){ref-type="fig"}). The enzyme comprises two domains: a copper-dependent peptidylglycine α-hydroxylating monooxygenase domain, which converts glycine-extended peptides into a hydroxyglycine intermediate; and a peptidyl α-hydroxyglycine α-amidating lyase domain, which converts the hydroxyglycine intermediate into an amidated product \[[@CR61]\]. The carboxy-terminal amine group of amidated peptides is essential for their biological activities \[[@CR63]\].Fig. 3Ascorbate-dependent synthesis of mature carboxy-terminal amidated vasopressin. Ascorbate is a cofactor for the metallo-enzyme peptidylglycine α-amidating monooxygenase (*PAM*). *AA* ascorbic acid, *DHA* dehydroascorbic acid

Pro-vasopressin and copeptin, which lack the carboxy-terminal amine present in mature vasopressin, have been proposed as surrogate measures of the mature amidated hormone because of their enhanced half-life in circulation \[[@CR64], [@CR65]\]. Pro-vasopressin and copeptin levels have been measured in patients with septic shock and were shown to be significantly associated with mortality, higher levels being observed in non-survivors than in survivors \[[@CR64], [@CR65]\]. Circulating copeptin levels are approximately 10-fold higher than those of vasopressin in severe sepsis and septic shock \[[@CR66]\]; however, it is not known whether this is simply due to enhanced stability of copeptin in circulation and/or decreased synthesis of mature vasopressin. The assumption that pro-vasopressin/copeptin levels reflect those of active vasopressin in a stoichiometric manner would not hold true if post-translational modification of glycine-extended vasopressin by PAM were affected through limited cofactor availability. In support of this premise, critically ill patients with sepsis and systemic inflammatory response syndrome (SIRS) have a significantly lower ratio of vasopressin to copeptin than patients after cardiac surgery \[[@CR67]\]. Thus, pro-vasopressin/copeptin should not be used as a surrogate marker for vasopressin levels in patients with hypovitaminosis C or hypoxia, both of which are common in severe sepsis and septic shock.

Conclusions {#Sec6}
===========

Ascorbate enhances the synthesis of the vasopressors norepinephrine and vasopressin by acting as a cofactor for their respective biosynthetic enzymes. As such, we hypothesise that administration of high-dose ascorbate in conditions of hypovitaminosis C (e.g. severe sepsis and septic shock) may support the endogenous synthesis of these vasoactive compounds and thus ameliorate the need for exogenously administered vasopressors. Ascorbate-dependent vasopressor synthesis represents a plausible physiological mechanism whereby ascorbate could act as an adjuvant therapy for severe sepsis and septic shock. Whether this mechanism translates into improved patient outcomes requires testing in well-designed clinical trials.
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